Karuna is a clinical-stage drug development company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders, including schizophrenia and Alzheimer\'s disease, as well as neuropathic pain.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/04/18 | $42,000,000 | Series A |
ARCH Venture Partners Steven Paul Wellcome Trust | undisclosed |
| 03/18/19 | $68,000,000 | Series B |
Alexandria Venture Investments ARCH Venture Partners  Eventide Asset Management Fidelity Management & Research Company Partner Fund Management PureTech Health Sands Capital Wellcome Trust | undisclosed |
| 04/01/19 | $12,000,000 | Series B Extension |
Sofinnova Ventures | undisclosed |
